🏛️ Verified NIH Record • Updated 2025-10-23
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (NCT03589339)
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Nanobiotix
🩺 Plain-English Summary (8th-Grade Level)
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of California San Francisco — San Francisco, California
- Moffitt Cancer Center — Tampa, Florida
- Emory University — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
- Northwell Health — Manhasset, New York
- University of North Carolina, School of Medicine — Chapel Hill, North Carolina
- Gabrail Cancer Center — Canton, Ohio
- St Luke's University Health Network — Bethlehem, Pennsylvania
- Sanford Cancer Center — Sioux Falls, South Dakota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Radiotherapy
Explore by condition: All Radiotherapy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.